Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.73 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PTGDR | Q13258 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.38 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2355901 | 0.85 | PTGER4 (1.00) | PTGER4PTGER2ALDH1A1PTGDR | |
| SCHEMBL2351632 | 0.81 | PTGER4 (1.00) | PTGER4PTGER2PTGDR | |
| SCHEMBL4090073 | 0.79 | PTGER4 (0.76) | PTGER4PTGER2ALDH1A1PTGDRMAPT | |
| SCHEMBL4089584 | 0.79 | PTGER4 (0.82) | PTGER4PTGER2PTGDR | |
| SCHEMBL14448600 | 0.67 | MMP13 (0.37) | PTGER4PDE2A | |
| SCHEMBL4088746 | 0.67 | PTGER4 (0.61) | PTGER4PTGER2MAPT | |
| SCHEMBL14448515 | 0.67 | MAPT (0.44) | PTGER4MAPTPDE2A | |
| SCHEMBL14448516 | 0.67 | MAPT (0.44) | PTGER4MAPTPDE2A | |
| SCHEMBL14448578 | 0.67 | MMP13 (0.46) | PDE2A | |
| SCHEMBL14448582 | 0.67 | MMP13 (0.46) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969394-B2 | Thiophenecarboxamide derivatives as EP4 receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2015-03-03 | — | — | US | disclosed |
| EP-2054401-B1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC (CA) | 2013-05-01 | — | — | EP | disclosed |
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | MERCK CANADA INC. (CA) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247596-A1 | THIOPHENECARBOXAMIDE DERIVATIVES AS EP4 RECEPTOR LIGANDS | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER2 3/4885ALDH1A1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.